Biomérieux Denmark Aps

The Company's principal activities BIOMÉRIEUX DENMARK ApS is an in-vitro diagnostics company within the bioMérieux S.A. Group. Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments. Estimation of the future development Next year, the sales are expected to increase by +25.2% in Clinical unit (and +7.9% in Industry) mainly thanks to the rebound post pandemic on other ranges, as well as conversion of Covid-related business to new opportunities. The significant increase in BGT23 versus Act 22 is indeed linked to the combination of 2 effects: * ACT22 was below our forecasted landing for FY22 (forecast made in Sept 22 /used as basis for BGT23 growth), which increased the % gap between ACT22 and BGT23. * Opportunities we have in terms of instruments deal in DK in 2023. Post financial year events After the end of the financial year, no events have occurred which may change the financial position of the entity substantially.

Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments., Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments.